NasdaqGS:AMRXPharmaceuticals
Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance
Amneal Pharmaceuticals stock has delivered a very strong 345.7% return over the past 3 years, yet its valuation checks lean more on the expensive side rather than flagging it as a clear bargain.
Over the last 3 years Amneal Pharmaceuticals has returned 345.7%, which puts extra focus on whether the current share price already reflects much of the good news.
Recent earnings strength and higher expectations for future revenue and profit can support the current valuation, but any disappointment...